PL2790712T3 - Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego - Google Patents

Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego

Info

Publication number
PL2790712T3
PL2790712T3 PL12858248T PL12858248T PL2790712T3 PL 2790712 T3 PL2790712 T3 PL 2790712T3 PL 12858248 T PL12858248 T PL 12858248T PL 12858248 T PL12858248 T PL 12858248T PL 2790712 T3 PL2790712 T3 PL 2790712T3
Authority
PL
Poland
Prior art keywords
subpopulation
treatment
nervous system
central nervous
human monocytes
Prior art date
Application number
PL12858248T
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Ester Yoles
Ravid Shechter
Omer Miller
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Publication of PL2790712T3 publication Critical patent/PL2790712T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/17Monocytes; Macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/414Nervous system antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12858248T 2011-12-14 2012-12-13 Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego PL2790712T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161570593P 2011-12-14 2011-12-14

Publications (1)

Publication Number Publication Date
PL2790712T3 true PL2790712T3 (pl) 2017-04-28

Family

ID=48611950

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12858248T PL2790712T3 (pl) 2011-12-14 2012-12-13 Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego

Country Status (15)

Country Link
US (1) US9314483B2 (pl)
EP (1) EP2790712B1 (pl)
JP (1) JP6148679B2 (pl)
KR (1) KR20140107439A (pl)
CN (1) CN104159590A (pl)
AU (2) AU2012354057B2 (pl)
BR (1) BR112014014560A8 (pl)
DK (1) DK2790712T3 (pl)
ES (1) ES2604356T3 (pl)
HU (1) HUE032096T2 (pl)
IN (1) IN2014MN01420A (pl)
MX (1) MX358589B (pl)
PL (1) PL2790712T3 (pl)
PT (1) PT2790712T (pl)
WO (1) WO2013088441A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3226971B2 (ja) 1992-08-04 2001-11-12 栗田工業株式会社 イオン交換装置の採水−再生サイクル制御装置
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
US10188679B2 (en) * 2013-05-22 2019-01-29 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of eye diseases and disorders
DK3234107T3 (da) * 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
US10722529B2 (en) 2015-12-03 2020-07-28 Temple University—Of the Commonwealth System of Higher Education Modulation of NAD+ metabolic pathways for treatment of disease
WO2020148769A1 (en) * 2019-01-16 2020-07-23 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Biomarker for cns disease modification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
US6194204B1 (en) * 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
MXPA04004813A (es) 2001-11-21 2004-08-11 Yeda Res & Dev Procedimientos para la produccion de leucocitos fagociticos mononucleares humanos.
JP2011515470A (ja) * 2008-03-28 2011-05-19 ステムサイト インコーポレーテッド 臍帯血細胞を用いた脳損傷の処置
US10188679B2 (en) * 2013-05-22 2019-01-29 Yeda Research And Development Co. Ltd Human monocyte sub-population for treatment of eye diseases and disorders

Also Published As

Publication number Publication date
US9314483B2 (en) 2016-04-19
JP6148679B2 (ja) 2017-06-14
PT2790712T (pt) 2016-12-02
CN104159590A (zh) 2014-11-19
EP2790712A4 (en) 2015-06-24
EP2790712B1 (en) 2016-08-31
KR20140107439A (ko) 2014-09-04
US20140363411A1 (en) 2014-12-11
WO2013088441A1 (en) 2013-06-20
IN2014MN01420A (pl) 2015-04-03
BR112014014560A8 (pt) 2017-07-04
MX358589B (es) 2018-08-27
EP2790712A1 (en) 2014-10-22
AU2017254830A1 (en) 2017-11-16
JP2015501835A (ja) 2015-01-19
HUE032096T2 (en) 2017-09-28
AU2012354057B2 (en) 2017-08-03
BR112014014560A2 (pt) 2017-06-13
DK2790712T3 (en) 2016-12-19
AU2012354057A1 (en) 2014-07-31
ES2604356T3 (es) 2017-03-06
MX2014007188A (es) 2015-09-22

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HRP20180559T1 (hr) Probiotičke terapije za autizam
EP2680775A4 (en) Cryogenic medical system
PL2747565T3 (pl) Sposoby zaprawiania nasion
EP3821941C0 (en) NEURAL STIMULATOR SYSTEM
EP2788078A4 (en) THERAPEUTIC NEUROMODULATION OF THE HEPATIC SYSTEM
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
EP2750611A4 (en) Lateral retractor system and methods of use
LT2885010T (lt) Tautopatijos gydymo būdai
EP2782540A4 (en) CHAIR WITH ROLLERS
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
BR112014004387A2 (pt) aparelho de tratamento de vestuário
PT3412687T (pt) Métodos de tratamento de dlbcl
EP2814441A4 (en) WHEELCHAIR SUSPENSION
BR112013021984A2 (pt) métodos e sistema de tratamento de poço
EP2742886A4 (en) SURGICAL SYSTEM
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
EP2750709A4 (en) TREATMENT OF KACHEXIE
EP2771213A4 (en) Assisted rescue system
ITMI20120445A1 (it) Dispositivo e procedimento per la produzione di spazzole circolari
EP2783256A4 (en) Therapeutic eyewear
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
IL229081A0 (en) Isoxazolines as therapeutic agents
PL2790712T3 (pl) Podpopulacja ludzkich monocytów do leczenia uszkodzenia ośrodkowego układu nerwowego
CO6880064A2 (es) Métodos terapéuticos